The Pacemakers Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Pacemakers Market:
https://www.thebusinessresearchcompany.com/report/pacemakers-global-market-report
According to The Business Research Company’s Pacemakers Global Market Report 2024, The pacemakers market size has grown strongly in recent years. It will grow from $5.23 billion in 2023 to $5.57 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to aging population, cardiovascular diseases, lifestyle-related health issues, regulatory approvals, heart attack survivors.
The pacemakers market size is expected to see strong growth in the next few years. It will grow to $7.25 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to telemedicine, public and private healthcare investment, pediatric and neonatal care, surgical techniques, miniaturization and leadless devices. Major trends in the forecast period include artificial intelligence (ai), wearable health tech, remote programming, electrophysiology procedures, technological advancements.
The increasing prevalence of cardiovascular diseases is contributing to the growth of the pacemaker market going forward. Cardiovascular diseases refer to diseases that affect the heart and blood vessels. Drug discovery technologies are used to discover new drugs for cardiovascular diseases. Pacemakers include flexible and insulated wires that are helpful in controlling cardiovascular diseases by controlling irregular heart rhythms. For instance, in 2021, according to the World Health Organization, a Switzerland-based government agency, India would account for one-fifth of the total deaths occurring from stroke and ischemic heart disease, mainly in younger adults. Additionally, according to the Center for Disease Control and prevention, an American national public health agency, in 2021, approximately 695,000 individuals in the United States lost their lives to heart disease, accounting for 1 out of every 5 fatalities. Therefore, the increasing prevalence of cardiovascular diseases will drive the growth of the pacemaker market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=6593&type=smp
The pacemakers market covered in this report is segmented –
1) By Type: MRI Compatible Pacemaker, Conventional Pacemaker
2) By Technology: Single-Chamber Pacemaker, Dual-Chamber Pacemaker, Biventricular or CRT Pacemaker
3) By Implantability: Implantable Pacemaker, External Pacemaker
4) By Application: Congestive Heart Failure, Arrhythmias, Bradycardia, Tachycardia
5) By End-User: Hospitals, Cardiac Care Centres, Ambulatory Surgical Centres, Other End Users
Major companies operating in the pacemaker market are developing innovative products such as leadless pacemakers to meet larger customer bases, more sales, and increase revenue. Leadless pacemakers are a type of cardiac implantable electronic device (CIED) used to regulate the heartbeat and treat certain heart rhythm disorders. For instance, in July 2023, Abbott, a US-based medical device company, announced the U.S. Food and Drug Administration (FDA) approval for the AVEIR dual chamber (DR) leadless pacemaker system. With more than 80% of individuals requiring a pacemaker needing dual-chamber pacing (simultaneous pacing of both the right atrium and right ventricle), this approval significantly expands access to leadless pacing for millions of people in the United States. AVEIR DR devices, enabled by Abbott’s proprietary i2i communication technology, offer synchronized or coordinated cardiac pacing between two leadless pacemakers based on a patient’s clinical requirements. The i2i technology operates by employing high-frequency pulses to transmit messages through the body’s naturally conductive blood, linking each leadless pacemaker. To facilitate dual-chamber therapy, each implant engages in real-time communication with its co-implanted counterpart, ensuring effective and synchronized cardiac pacing.
The pacemakers market report table of contents includes:
.
.
.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Overview and Scope Vacuum gas oil is referred to as a semi-liquid form of oil…
Overview and Scope Vaccine adjuvants are compounds or ingredients used in vaccines that enhance the…
Overview and Scope Veterinary chemistry analyzer can be defined as an instrument used for testing…
Overview and Scope Uterine fibroids treatment refers to treatment procedures related to uterine fibroids. Uterine…
Overview and Scope Urea refers to a safe, practical substance with a long history. It…
Overview and Scope Transgenic seed, also known as genetically modified seed, refers to a seed…